Share on LinkedInShare on LinkedIn

ARTICLE · 27 JULY 2015

A Fractured Federal Circuit Panel Interprets The Biosimilars Patent Resolution Procedures

The BPCIA established procedures to define and narrow disputes between biosimilar applicants and reference product sponsors after the (k) application is filed.

United StatesIntellectual Property

On July 21, the Federal Circuit interpreted the patent litigation procedures and requirements of the Biologics Price Competition and Innovation Act (BPCIA), including whether a company submitting an abbreviated BLA ("k applicant") is required to comply with the BPCIA's detailed patent challenge process. In a fractured decision, Judges Lourie and Chen joined in holding that a (k) applicant does not violate the BPCIA when it fails to disclose its application and manufacturing information by the statutory deadline. Judge Newman dissented. Then, Judges Lourie and Newman, with Judge Chen dissenting, joined in holding that the (k) applicant is nevertheless required to give a 180-day notice of commercial marketing after FDA approval of its biosimilar product, giving the reference product sponsor six months to seek a preliminary injunction to block launch of the product until resolution of any patent disputes.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from